Volume 96 Issue 11 | p. 19 | Concentrates
Issue Date: March 12, 2018

Merck licenses cancer drug from Eisai

Department: Business
Keywords: Oncology, Merck, Eisai, Keytruda

Merck & Co. will pay Eisai $750 million plus milestone payments of up to $4 billion to jointly develop Eisai’s lenvatinib mesylate, a small-molecule tyrosine kinase inhibitor already approved to treat certain cancers. The two firms will develop the drug, sold as Lenvima, as a monotherapy and in combination with Merck’s Keytruda anti-PD-1 cancer therapy. “There is strong scientific evidence supporting synergistic effects of Keytruda when used in combination with Lenvima,” says Roger M. Perlmutter, president of Merck Research Laboratories.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment